Treatment of pulmonary embolism: The use of low-molecular-weight heparin in the inpatient and outpatient settings.

@article{Hull2008TreatmentOP,
  title={Treatment of pulmonary embolism: The use of low-molecular-weight heparin in the inpatient and outpatient settings.},
  author={Russell Douglas Hull},
  journal={Thrombosis and haemostasis},
  year={2008},
  volume={99 3},
  pages={
          502-10
        }
}
Pulmonary embolism (PE) remains a major clinical problem associated with considerable mortality and morbidity. In patients with PE, appropriate anticoagulant therapy has been shown to significantly reduce both recurrence and mortality. Low-molecular-weight heparin (LMWH) is at least as effective as unfractionated heparin (UFH) in the treatment of PE, with a similar risk of bleeding. Furthermore, LMWH offers more predictable pharmacokinetics and anticoagulant effects. As a result, current… CONTINUE READING

Similar Papers

Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 13 CITATIONS

Modulation of Sickle Red Blood Cell Adhesion and its Associated Changes in Biomarkers by Sulfated Nonanticoagulant Heparin Derivative.

  • Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • 2016
VIEW 1 EXCERPT
CITES BACKGROUND

Treatment of low-risk pulmonary embolism patients in a chest pain unit.

  • Critical pathways in cardiology
  • 2010
VIEW 1 EXCERPT
CITES BACKGROUND